MOLECULAR METABOLISM, A NEW BIOTECH FIRM, ANNOUNCES COLLABORATION WITH JOSLIN DIABETES CENTER

December 4, 2013

Pittsfield, MA – A new biotechnology firm, Molecular Metabolism, LLC., born out of a relationship with Nuclea Biotechnologies, has chosen Pittsfield as their company’s headquarters. Molecular Metabolism is currently in the process of assembling its management team and is expected to create seven to ten new jobs locally.

Molecular Metabolism is a development stage company focused on the discovery of biomarkers and therapeutic based targets for metabolic syndromes and central nervous system (CNS) diseases. These biomarkers can aid physicians in determining the best, individualized courses of treatment for patients suffering from metabolic conditions, such as obesity, fatty liver disease, and diabetes.

Molecular Metabolism and Nuclea Biotechnologies have established a collaboration with Joslin Diabetes Center, the diabetes research and care organization affiliated with Harvard Medical School, in biomarkers of insulin resistance and applications of imaging. The initial research in imaging will help identify “brown fat” in humans, a type of fat that drives energy expenditure and may potentially benefit metabolic endpoints. 

Molecular Metabolism’s collaboration with Joslin will assess the feasibility of using MRI and Infrared thermal imaging to measure the mass and activity of cold-activated human brown adipose tissues (BAT). The partners believe that the results of this research will provide greater insight into how Type 2 diabetes is evaluated and diagnosed with the goal of screening new therapies that stimulate generation of brown fat.  This work will be done with Dr. Aaron Cypess, Assistant Professor and Investigator at Joslin Diabetes Center.

”Diagnostics and imaging techniques can make a significant impact on the detection and management of diabetes and its complications, and Joslin’s interest in brown fat stimulation and energy expenditure is an exciting area to apply this to,” said Dr. Aaron Cypess,.  “We hope to advance our techniques to a stage where brown fat can be easily detected and quantified,” he added.

“This collaboration with Joslin will help initiate Molecular Metabolism’s work within the metabolic disease realm,” said Patrick Muraca, interim President of Molecular Metabolism and President and CEO of Nuclea Biotechnologies. “Molecular Metabolism will collaborate with Nuclea in the research and development of the biomarkers. Joslin is a tremendous partner and I believe this research in brown fat imaging will help us as we work to create new tools for the treatment and diagnosis of Type 2 diabetes.”

Joslin will also work with Nuclea Biotechnologies, under the direction of Dr. Mary Elizabeth Patti, Assistant Professor and Investigator at Joslin, to apply proteomic analyses on patient cohorts in order to understand pathways leading to insulin resistance and develop biomarkers of risk of Type 2 diabetes.

“We are very pleased to be partnering with Nuclea to identify new biomarkers which could potentially be used to determine risk of diabetes and other metabolic disease,” said Dr. Mary Elizabeth Patti.  “These efforts are crucial in the fight against diabetes, so that we can identify those individuals at the highest risk of disease, and also to individualize optimal treatment strategies.” 

 

About Nuclea

Nuclea Biotechnologies, Inc. is headquartered in Pittsfield, Massachusetts with additional operations in Worcester, Massachusetts. Nuclea has developed and is commercializing unique diagnostic tests for colon, breast, leukaemia, lung and prostate cancer. Nuclea also performs research leading to novel molecular oncology companion diagnostics for the pharmaceutical and biotechnology industries. www.nucleabio.com

 

About Joslin

Joslin Diabetes Center, based in Boston, Massachusetts, undertakes diabetes research, clinical care, education and health and wellness programs on a global scale. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real progress in preventing and curing diabetes  Joslin is an independent, nonprofit institution affiliated with Harvard Medical School, and is recognized worldwide for driving innovative solutions in diabetes prevention, research, education, and care.

 

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.